Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-09

AUTHORS

Noriaki Nakaya, Kyoichi Mizuno, Yasuo Ohashi, Tamio Teramoto, Shinji Yokoyama, Katsumi Hirahara, Masahiro Mizutani, Haruo Nakamura

ABSTRACT

Background: Limited data are available regarding the relationship between age and the effect of HMG-CoA reductase inhibitor (statin) treatment.Objective: The aim of the present analysis was to evaluate the relationships between age, baseline patient characteristics, and pravastatin treatment with respect to the development of cardiovascular disease (CVD) in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study, a large-scale clinical study conducted in Japanese patients with mild or moderate hyperlipidaemia to evaluate the primary preventive effect of pravastatin against coronary heart disease.Methods: To compare the prevalence of CVD risk factors, the incidence of CVD in relation to each risk factor, and final values and changes in lipid parameters, the 7832 patients were classified into six age groups: <45, 45–9, 50–54, 55–59, 60–64 and ≤65 years. The relationship between pravastatin (10–20mg/day) treatment efficacy and aging and the incidence of events in relation to the age groups were compared using the multivariable Cox proportional hazards model.Results: The prevalences of diabetes mellitus and hypertension were higher in older men than in younger men, while the prevalences of smoking and obesity were higher in younger men. However, a similar difference in risk factors was not seen in women. High-density lipoprotein cholesterol was higher in women than in men across all age groups. Triglycerides were higher in younger men than in older men and all groups of women. The mean follow-up levels of total cholesterol and low-density lipoprotein cholesterol were lower in older patients than in younger patients. Pravastatin (10–20mg/day) reduced the risk of CVD by about 30–40% across all age groups, and there was no difference between men and women. Of particular note in this analysis, CVD risk was markedly reduced in older women compared with younger women (53% vs 30% in women aged ≥65 vs ≥45 years).Conclusion: A similar satisfactory risk reduction for CVD was achieved with low-dose pravastatin in all men and in older women in particular, despite differences in the prevalence of risk factors.Trial registration: ClinicalTrials.gov Identifier: NCT00211705. More... »

PAGES

681-692

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11595620-000000000-00000

DOI

http://dx.doi.org/10.2165/11595620-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051722302

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21815708


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asians", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coronary Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypercholesterolemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pravastatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nakaya Clinic, 4-7-8 Higashinakano Nakano-ku, 164-0003, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Nakaya Clinic, 4-7-8 Higashinakano Nakano-ku, 164-0003, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakaya", 
        "givenName": "Noriaki", 
        "id": "sg:person.01123443575.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123443575.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Nippon Medical School, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410821.e", 
          "name": [
            "Department of Internal Medicine, Nippon Medical School, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuno", 
        "givenName": "Kyoichi", 
        "id": "sg:person.01224612517.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224612517.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohashi", 
        "givenName": "Yasuo", 
        "id": "sg:person.016471405272.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016471405272.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.264706.1", 
          "name": [
            "Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Teramoto", 
        "givenName": "Tamio", 
        "id": "sg:person.0603243740.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603243740.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nagoya City University Graduate School of Medical Science, Nagoya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.260433.0", 
          "name": [
            "Nagoya City University Graduate School of Medical Science, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokoyama", 
        "givenName": "Shinji", 
        "id": "sg:person.01174452746.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174452746.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hirahara Internal Clinic, Niigata, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Hirahara Internal Clinic, Niigata, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hirahara", 
        "givenName": "Katsumi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Asahiyama Internal Clinic, Hokkaido, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Asahiyama Internal Clinic, Hokkaido, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizutani", 
        "givenName": "Masahiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mitsukoshi Health and Welfare Foundation, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.490945.5", 
          "name": [
            "Mitsukoshi Health and Welfare Foundation, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakamura", 
        "givenName": "Haruo", 
        "id": "sg:person.015301342162.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015301342162.18"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-09", 
    "datePublishedReg": "2011-09-01", 
    "description": "Background: Limited data are available regarding the relationship between age and the effect of HMG-CoA reductase inhibitor (statin) treatment.Objective: The aim of the present analysis was to evaluate the relationships between age, baseline patient characteristics, and pravastatin treatment with respect to the development of cardiovascular disease (CVD) in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study, a large-scale clinical study conducted in Japanese patients with mild or moderate hyperlipidaemia to evaluate the primary preventive effect of pravastatin against coronary heart disease.Methods: To compare the prevalence of CVD risk factors, the incidence of CVD in relation to each risk factor, and final values and changes in lipid parameters, the 7832 patients were classified into six age groups: <45, 45\u20139, 50\u201354, 55\u201359, 60\u201364 and \u226465 years. The relationship between pravastatin (10\u201320mg/day) treatment efficacy and aging and the incidence of events in relation to the age groups were compared using the multivariable Cox proportional hazards model.Results: The prevalences of diabetes mellitus and hypertension were higher in older men than in younger men, while the prevalences of smoking and obesity were higher in younger men. However, a similar difference in risk factors was not seen in women. High-density lipoprotein cholesterol was higher in women than in men across all age groups. Triglycerides were higher in younger men than in older men and all groups of women. The mean follow-up levels of total cholesterol and low-density lipoprotein cholesterol were lower in older patients than in younger patients. Pravastatin (10\u201320mg/day) reduced the risk of CVD by about 30\u201340% across all age groups, and there was no difference between men and women. Of particular note in this analysis, CVD risk was markedly reduced in older women compared with younger women (53% vs 30% in women aged \u226565 vs \u226545 years).Conclusion: A similar satisfactory risk reduction for CVD was achieved with low-dose pravastatin in all men and in older women in particular, despite differences in the prevalence of risk factors.Trial registration: ClinicalTrials.gov Identifier: NCT00211705.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/11595620-000000000-00000", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100990", 
        "issn": [
          "1170-229X", 
          "1179-1969"
        ], 
        "name": "Drugs & Aging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "keywords": [
      "risk factors", 
      "cardiovascular disease", 
      "age groups", 
      "lipoprotein cholesterol", 
      "older women", 
      "older men", 
      "multivariable Cox proportional hazards models", 
      "young men", 
      "HMG-CoA reductase inhibitor treatment", 
      "incidence of CVD", 
      "high-density lipoprotein cholesterol", 
      "low-density lipoprotein cholesterol", 
      "risk of CVD", 
      "Cox proportional hazards model", 
      "primary prevention group", 
      "Adult Japanese (MEGA) Study", 
      "primary preventive effect", 
      "low-dose pravastatin", 
      "CVD risk factors", 
      "baseline patient characteristics", 
      "prevalence of smoking", 
      "large-scale clinical studies", 
      "coronary heart disease", 
      "reductase inhibitor treatment", 
      "incidence of events", 
      "proportional hazards model", 
      "group of women", 
      "moderate hyperlipidaemia", 
      "dose pravastatin", 
      "mean follow", 
      "patient characteristics", 
      "older patients", 
      "younger patients", 
      "CVD risk", 
      "diabetes mellitus", 
      "total cholesterol", 
      "elevated cholesterol", 
      "lipid parameters", 
      "preventive effect", 
      "heart disease", 
      "Japanese patients", 
      "prevention group", 
      "clinical studies", 
      "hazards model", 
      "treatment efficacy", 
      "inhibitor treatment", 
      "patients", 
      "pravastatin", 
      "young women", 
      "prevalence", 
      "cholesterol", 
      "women", 
      "disease", 
      "limited data", 
      "men", 
      "risk reduction", 
      "age", 
      "incidence", 
      "Similar differences", 
      "Japanese studies", 
      "treatment", 
      "group", 
      "risk", 
      "hypertension", 
      "hyperlipidaemia", 
      "mellitus", 
      "factors", 
      "smoking", 
      "obesity", 
      "differences", 
      "follow", 
      "triglycerides", 
      "efficacy", 
      "study", 
      "particular note", 
      "effect", 
      "aim", 
      "years", 
      "present analysis", 
      "relationship", 
      "management", 
      "aging", 
      "levels", 
      "events", 
      "reduction", 
      "analysis", 
      "changes", 
      "data", 
      "development", 
      "relation", 
      "Japanese", 
      "characteristics", 
      "final value", 
      "values", 
      "identifiers", 
      "note", 
      "model", 
      "respect", 
      "parameters"
    ], 
    "name": "Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese", 
    "pagination": "681-692", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051722302"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11595620-000000000-00000"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21815708"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11595620-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1051722302"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/11595620-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11595620-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11595620-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11595620-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11595620-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

302 TRIPLES      20 PREDICATES      144 URIs      134 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11595620-000000000-00000 schema:about N268ad114ef1c4b67b15706f3a682b46c
2 N2cd59c0c120541ff94e8284bc5b7dc65
3 N30adf08fd9074448bd7f5794e94b9b5b
4 N39651d122b5946158c16432b7ce5a629
5 N422c77cbe7fb447987d3cac55fdf04b4
6 N43a333e2f0cd4d0faae4afd3c738eb35
7 N45d1f902884642f0b93caf426915a245
8 N49241be3326244868c8124f0a12941d5
9 N89dea255a4ef4739bc03d70e8be60351
10 Na5fa2b3102074ec5a132f85c90e90e0d
11 Naf35153087f14f03a62b224a12ae0a97
12 Nbb7a297ffe3e440cb9e0c25e4627f3fb
13 Nc110acfd620c429084c2bbba3fcb8f61
14 Nd3aa43df3e4544619b95b4ceb33a21c8
15 Ne1cfc623797a43109fd93025583dca5c
16 Ne320a3cd8a624b54a12490e84e8b3798
17 Ne4ee1def400b417c9ed136865960c44b
18 anzsrc-for:11
19 anzsrc-for:1102
20 anzsrc-for:1103
21 anzsrc-for:1117
22 schema:author N2be6df2f47344c688814eef4d518ddea
23 schema:datePublished 2011-09
24 schema:datePublishedReg 2011-09-01
25 schema:description Background: Limited data are available regarding the relationship between age and the effect of HMG-CoA reductase inhibitor (statin) treatment.Objective: The aim of the present analysis was to evaluate the relationships between age, baseline patient characteristics, and pravastatin treatment with respect to the development of cardiovascular disease (CVD) in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study, a large-scale clinical study conducted in Japanese patients with mild or moderate hyperlipidaemia to evaluate the primary preventive effect of pravastatin against coronary heart disease.Methods: To compare the prevalence of CVD risk factors, the incidence of CVD in relation to each risk factor, and final values and changes in lipid parameters, the 7832 patients were classified into six age groups: <45, 45–9, 50–54, 55–59, 60–64 and ≤65 years. The relationship between pravastatin (10–20mg/day) treatment efficacy and aging and the incidence of events in relation to the age groups were compared using the multivariable Cox proportional hazards model.Results: The prevalences of diabetes mellitus and hypertension were higher in older men than in younger men, while the prevalences of smoking and obesity were higher in younger men. However, a similar difference in risk factors was not seen in women. High-density lipoprotein cholesterol was higher in women than in men across all age groups. Triglycerides were higher in younger men than in older men and all groups of women. The mean follow-up levels of total cholesterol and low-density lipoprotein cholesterol were lower in older patients than in younger patients. Pravastatin (10–20mg/day) reduced the risk of CVD by about 30–40% across all age groups, and there was no difference between men and women. Of particular note in this analysis, CVD risk was markedly reduced in older women compared with younger women (53% vs 30% in women aged ≥65 vs ≥45 years).Conclusion: A similar satisfactory risk reduction for CVD was achieved with low-dose pravastatin in all men and in older women in particular, despite differences in the prevalence of risk factors.Trial registration: ClinicalTrials.gov Identifier: NCT00211705.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N26d5c9a70f964f55969782797398c332
29 Nd34f1d40c93944419a5ef3ee472ec3aa
30 sg:journal.1100990
31 schema:keywords Adult Japanese (MEGA) Study
32 CVD risk
33 CVD risk factors
34 Cox proportional hazards model
35 HMG-CoA reductase inhibitor treatment
36 Japanese
37 Japanese patients
38 Japanese studies
39 Similar differences
40 age
41 age groups
42 aging
43 aim
44 analysis
45 baseline patient characteristics
46 cardiovascular disease
47 changes
48 characteristics
49 cholesterol
50 clinical studies
51 coronary heart disease
52 data
53 development
54 diabetes mellitus
55 differences
56 disease
57 dose pravastatin
58 effect
59 efficacy
60 elevated cholesterol
61 events
62 factors
63 final value
64 follow
65 group
66 group of women
67 hazards model
68 heart disease
69 high-density lipoprotein cholesterol
70 hyperlipidaemia
71 hypertension
72 identifiers
73 incidence
74 incidence of CVD
75 incidence of events
76 inhibitor treatment
77 large-scale clinical studies
78 levels
79 limited data
80 lipid parameters
81 lipoprotein cholesterol
82 low-density lipoprotein cholesterol
83 low-dose pravastatin
84 management
85 mean follow
86 mellitus
87 men
88 model
89 moderate hyperlipidaemia
90 multivariable Cox proportional hazards models
91 note
92 obesity
93 older men
94 older patients
95 older women
96 parameters
97 particular note
98 patient characteristics
99 patients
100 pravastatin
101 present analysis
102 prevalence
103 prevalence of smoking
104 prevention group
105 preventive effect
106 primary prevention group
107 primary preventive effect
108 proportional hazards model
109 reductase inhibitor treatment
110 reduction
111 relation
112 relationship
113 respect
114 risk
115 risk factors
116 risk of CVD
117 risk reduction
118 smoking
119 study
120 total cholesterol
121 treatment
122 treatment efficacy
123 triglycerides
124 values
125 women
126 years
127 young men
128 young women
129 younger patients
130 schema:name Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese
131 schema:pagination 681-692
132 schema:productId N0eb0bdaf2236485d93b4bb43f78ce6eb
133 N40933493eb174831a3e97d366e5ad4d4
134 Nc4ccba6ddea8499c9edc62b95d32a90f
135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051722302
136 https://doi.org/10.2165/11595620-000000000-00000
137 schema:sdDatePublished 2022-09-02T15:55
138 schema:sdLicense https://scigraph.springernature.com/explorer/license/
139 schema:sdPublisher N5398f752127947bfb1e70d325077b6c5
140 schema:url https://doi.org/10.2165/11595620-000000000-00000
141 sgo:license sg:explorer/license/
142 sgo:sdDataset articles
143 rdf:type schema:ScholarlyArticle
144 N0a5bc7dbebff426697d33f113d6b3db2 rdf:first sg:person.016471405272.86
145 rdf:rest N60a8f6772b114de7ad97714ba9e48494
146 N0eb0bdaf2236485d93b4bb43f78ce6eb schema:name pubmed_id
147 schema:value 21815708
148 rdf:type schema:PropertyValue
149 N120971d1ed964149b0e09e8b8e5cbb70 rdf:first sg:person.01174452746.37
150 rdf:rest Nc26771e32b984cda9ca585b48c557d32
151 N268ad114ef1c4b67b15706f3a682b46c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Risk Factors
153 rdf:type schema:DefinedTerm
154 N26d5c9a70f964f55969782797398c332 schema:volumeNumber 28
155 rdf:type schema:PublicationVolume
156 N2be6df2f47344c688814eef4d518ddea rdf:first sg:person.01123443575.58
157 rdf:rest N7d4ecc06568a4a51aaaad0dc220e3ce8
158 N2cd59c0c120541ff94e8284bc5b7dc65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Female
160 rdf:type schema:DefinedTerm
161 N30adf08fd9074448bd7f5794e94b9b5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Adult
163 rdf:type schema:DefinedTerm
164 N39651d122b5946158c16432b7ce5a629 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Stroke
166 rdf:type schema:DefinedTerm
167 N3f1b22961bd540b9a3bf07d3f7f08843 schema:affiliation grid-institutes:None
168 schema:familyName Mizutani
169 schema:givenName Masahiro
170 rdf:type schema:Person
171 N40933493eb174831a3e97d366e5ad4d4 schema:name dimensions_id
172 schema:value pub.1051722302
173 rdf:type schema:PropertyValue
174 N422c77cbe7fb447987d3cac55fdf04b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Asians
176 rdf:type schema:DefinedTerm
177 N43a333e2f0cd4d0faae4afd3c738eb35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Middle Aged
179 rdf:type schema:DefinedTerm
180 N4448cc9ef1a24837b1f9b1d22277ee3b schema:affiliation grid-institutes:None
181 schema:familyName Hirahara
182 schema:givenName Katsumi
183 rdf:type schema:Person
184 N45d1f902884642f0b93caf426915a245 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Coronary Disease
186 rdf:type schema:DefinedTerm
187 N49241be3326244868c8124f0a12941d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Male
189 rdf:type schema:DefinedTerm
190 N5398f752127947bfb1e70d325077b6c5 schema:name Springer Nature - SN SciGraph project
191 rdf:type schema:Organization
192 N60a8f6772b114de7ad97714ba9e48494 rdf:first sg:person.0603243740.66
193 rdf:rest N120971d1ed964149b0e09e8b8e5cbb70
194 N7d4ecc06568a4a51aaaad0dc220e3ce8 rdf:first sg:person.01224612517.39
195 rdf:rest N0a5bc7dbebff426697d33f113d6b3db2
196 N88cab578c76d47fbae5840cdd3b54902 rdf:first N3f1b22961bd540b9a3bf07d3f7f08843
197 rdf:rest Ne0be476473ed47318c171c210583aff3
198 N89dea255a4ef4739bc03d70e8be60351 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Aged
200 rdf:type schema:DefinedTerm
201 Na5fa2b3102074ec5a132f85c90e90e0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Pravastatin
203 rdf:type schema:DefinedTerm
204 Naf35153087f14f03a62b224a12ae0a97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Humans
206 rdf:type schema:DefinedTerm
207 Nbb7a297ffe3e440cb9e0c25e4627f3fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Cardiovascular Diseases
209 rdf:type schema:DefinedTerm
210 Nc110acfd620c429084c2bbba3fcb8f61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Hypercholesterolemia
212 rdf:type schema:DefinedTerm
213 Nc26771e32b984cda9ca585b48c557d32 rdf:first N4448cc9ef1a24837b1f9b1d22277ee3b
214 rdf:rest N88cab578c76d47fbae5840cdd3b54902
215 Nc4ccba6ddea8499c9edc62b95d32a90f schema:name doi
216 schema:value 10.2165/11595620-000000000-00000
217 rdf:type schema:PropertyValue
218 Nd34f1d40c93944419a5ef3ee472ec3aa schema:issueNumber 9
219 rdf:type schema:PublicationIssue
220 Nd3aa43df3e4544619b95b4ceb33a21c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Age Factors
222 rdf:type schema:DefinedTerm
223 Ne0be476473ed47318c171c210583aff3 rdf:first sg:person.015301342162.18
224 rdf:rest rdf:nil
225 Ne1cfc623797a43109fd93025583dca5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Follow-Up Studies
227 rdf:type schema:DefinedTerm
228 Ne320a3cd8a624b54a12490e84e8b3798 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
229 schema:name Cholesterol
230 rdf:type schema:DefinedTerm
231 Ne4ee1def400b417c9ed136865960c44b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Dose-Response Relationship, Drug
233 rdf:type schema:DefinedTerm
234 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
235 schema:name Medical and Health Sciences
236 rdf:type schema:DefinedTerm
237 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
238 schema:name Cardiorespiratory Medicine and Haematology
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
241 schema:name Clinical Sciences
242 rdf:type schema:DefinedTerm
243 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
244 schema:name Public Health and Health Services
245 rdf:type schema:DefinedTerm
246 sg:journal.1100990 schema:issn 1170-229X
247 1179-1969
248 schema:name Drugs & Aging
249 schema:publisher Springer Nature
250 rdf:type schema:Periodical
251 sg:person.01123443575.58 schema:affiliation grid-institutes:None
252 schema:familyName Nakaya
253 schema:givenName Noriaki
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123443575.58
255 rdf:type schema:Person
256 sg:person.01174452746.37 schema:affiliation grid-institutes:grid.260433.0
257 schema:familyName Yokoyama
258 schema:givenName Shinji
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174452746.37
260 rdf:type schema:Person
261 sg:person.01224612517.39 schema:affiliation grid-institutes:grid.410821.e
262 schema:familyName Mizuno
263 schema:givenName Kyoichi
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224612517.39
265 rdf:type schema:Person
266 sg:person.015301342162.18 schema:affiliation grid-institutes:grid.490945.5
267 schema:familyName Nakamura
268 schema:givenName Haruo
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015301342162.18
270 rdf:type schema:Person
271 sg:person.016471405272.86 schema:affiliation grid-institutes:grid.26999.3d
272 schema:familyName Ohashi
273 schema:givenName Yasuo
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016471405272.86
275 rdf:type schema:Person
276 sg:person.0603243740.66 schema:affiliation grid-institutes:grid.264706.1
277 schema:familyName Teramoto
278 schema:givenName Tamio
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603243740.66
280 rdf:type schema:Person
281 grid-institutes:None schema:alternateName Asahiyama Internal Clinic, Hokkaido, Japan
282 Hirahara Internal Clinic, Niigata, Japan
283 Nakaya Clinic, 4-7-8 Higashinakano Nakano-ku, 164-0003, Tokyo, Japan
284 schema:name Asahiyama Internal Clinic, Hokkaido, Japan
285 Hirahara Internal Clinic, Niigata, Japan
286 Nakaya Clinic, 4-7-8 Higashinakano Nakano-ku, 164-0003, Tokyo, Japan
287 rdf:type schema:Organization
288 grid-institutes:grid.260433.0 schema:alternateName Nagoya City University Graduate School of Medical Science, Nagoya, Japan
289 schema:name Nagoya City University Graduate School of Medical Science, Nagoya, Japan
290 rdf:type schema:Organization
291 grid-institutes:grid.264706.1 schema:alternateName Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
292 schema:name Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
293 rdf:type schema:Organization
294 grid-institutes:grid.26999.3d schema:alternateName Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, Tokyo, Japan
295 schema:name Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, Tokyo, Japan
296 rdf:type schema:Organization
297 grid-institutes:grid.410821.e schema:alternateName Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
298 schema:name Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
299 rdf:type schema:Organization
300 grid-institutes:grid.490945.5 schema:alternateName Mitsukoshi Health and Welfare Foundation, Tokyo, Japan
301 schema:name Mitsukoshi Health and Welfare Foundation, Tokyo, Japan
302 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...